Targeting MERTK and AXL in <i>EGFR</i> Mutant Non-Small Cell Lung Cancer
MERTK and AXL are members of the TAM family of receptor tyrosine kinases and are abnormally expressed in 69% and 93% of non-small cell lung cancers (NSCLCs), respectively. Expression of MERTK and/or AXL provides a survival advantage for NSCLC cells and correlates with lymph node metastasis, drug res...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-11-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/13/22/5639 |
| _version_ | 1797510975032655872 |
|---|---|
| author | Dan Yan H. Shelton Earp Deborah DeRyckere Douglas K. Graham |
| author_facet | Dan Yan H. Shelton Earp Deborah DeRyckere Douglas K. Graham |
| author_sort | Dan Yan |
| collection | DOAJ |
| description | MERTK and AXL are members of the TAM family of receptor tyrosine kinases and are abnormally expressed in 69% and 93% of non-small cell lung cancers (NSCLCs), respectively. Expression of MERTK and/or AXL provides a survival advantage for NSCLC cells and correlates with lymph node metastasis, drug resistance, and disease progression in patients with NSCLC. The TAM receptors on host tumor infiltrating cells also play important roles in the immunosuppressive tumor microenvironment. Thus, MERTK and AXL are attractive biologic targets for NSCLC treatment. Here, we will review physiologic and oncologic roles for MERTK and AXL with an emphasis on the potential to target these kinases in NSCLCs with activating EGFR mutations. |
| first_indexed | 2024-03-10T05:39:49Z |
| format | Article |
| id | doaj.art-f008783afb8b4deca24ca6395ea261cc |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-10T05:39:49Z |
| publishDate | 2021-11-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-f008783afb8b4deca24ca6395ea261cc2023-11-22T22:41:08ZengMDPI AGCancers2072-66942021-11-011322563910.3390/cancers13225639Targeting MERTK and AXL in <i>EGFR</i> Mutant Non-Small Cell Lung CancerDan Yan0H. Shelton Earp1Deborah DeRyckere2Douglas K. Graham3Aflac Cancer and Blood Disorders Center, Children’s Healthcare of Atlanta, Department of Pediatrics, Emory University, Atlanta, GA 30322, USAUNC Lineberger Comprehensive Cancer Center, Department of Medicine, Chapel Hill, NC 27599, USAAflac Cancer and Blood Disorders Center, Children’s Healthcare of Atlanta, Department of Pediatrics, Emory University, Atlanta, GA 30322, USAAflac Cancer and Blood Disorders Center, Children’s Healthcare of Atlanta, Department of Pediatrics, Emory University, Atlanta, GA 30322, USAMERTK and AXL are members of the TAM family of receptor tyrosine kinases and are abnormally expressed in 69% and 93% of non-small cell lung cancers (NSCLCs), respectively. Expression of MERTK and/or AXL provides a survival advantage for NSCLC cells and correlates with lymph node metastasis, drug resistance, and disease progression in patients with NSCLC. The TAM receptors on host tumor infiltrating cells also play important roles in the immunosuppressive tumor microenvironment. Thus, MERTK and AXL are attractive biologic targets for NSCLC treatment. Here, we will review physiologic and oncologic roles for MERTK and AXL with an emphasis on the potential to target these kinases in NSCLCs with activating EGFR mutations.https://www.mdpi.com/2072-6694/13/22/5639MERTKAXLTAM familyreceptor tyrosine kinasetargeted therapyNSCLC |
| spellingShingle | Dan Yan H. Shelton Earp Deborah DeRyckere Douglas K. Graham Targeting MERTK and AXL in <i>EGFR</i> Mutant Non-Small Cell Lung Cancer Cancers MERTK AXL TAM family receptor tyrosine kinase targeted therapy NSCLC |
| title | Targeting MERTK and AXL in <i>EGFR</i> Mutant Non-Small Cell Lung Cancer |
| title_full | Targeting MERTK and AXL in <i>EGFR</i> Mutant Non-Small Cell Lung Cancer |
| title_fullStr | Targeting MERTK and AXL in <i>EGFR</i> Mutant Non-Small Cell Lung Cancer |
| title_full_unstemmed | Targeting MERTK and AXL in <i>EGFR</i> Mutant Non-Small Cell Lung Cancer |
| title_short | Targeting MERTK and AXL in <i>EGFR</i> Mutant Non-Small Cell Lung Cancer |
| title_sort | targeting mertk and axl in i egfr i mutant non small cell lung cancer |
| topic | MERTK AXL TAM family receptor tyrosine kinase targeted therapy NSCLC |
| url | https://www.mdpi.com/2072-6694/13/22/5639 |
| work_keys_str_mv | AT danyan targetingmertkandaxliniegfrimutantnonsmallcelllungcancer AT hsheltonearp targetingmertkandaxliniegfrimutantnonsmallcelllungcancer AT deborahderyckere targetingmertkandaxliniegfrimutantnonsmallcelllungcancer AT douglaskgraham targetingmertkandaxliniegfrimutantnonsmallcelllungcancer |